Talphera (TLPH) Operating Expenses (2010 - 2026)
Talphera (TLPH) posted Operating Expenses of $3.9 million for Q2 2026, down 0.61% on a QoQ basis from $3.9 million in Q1 2026, and up 6.26% year-over-year from $3.7 million in Q2 2025.
Analysis
Talphera (TLPH) Operating Expenses (2010 - 2026) Analysis & Trends
Talphera has reported Operating Expenses for 17 years, with the latest figure at $3.9 million in Q2 2026.
- On a quarterly basis, Operating Expenses rose 6.26% year-over-year to $3.9 million in Q2 2026; TTM through Jun 2026 was $14.7 million, a 10.22% increase from a year earlier, with the FY2025 full-year figure at $13.5 million, down 11.41% from the prior year.
- Operating Expenses was $3.9 million for Q2 2026 at Talphera, down from $3.9 million in the prior quarter.
- The five-year high for Operating Expenses was $10.0 million in Q2 2022, with the low at $2.9 million in Q1 2025.
- Average Operating Expenses over 5 years is $4.6 million, with a median of $3.9 million recorded in 2026.
- The sharpest annual moves came in 2023 and 2026: Operating Expenses sank 57.59% in 2023, then surged 34.15% in 2026.
- Over 5 years, Operating Expenses stood at $5.9 million in 2022, then retreated by 22.46% to $4.6 million in 2023, then plunged by 34.36% to $3.0 million in 2024, then gained by 15.25% to $3.5 million in 2025, then increased by 13.64% to $3.9 million in 2026.
- The last three Operating Expenses figures came in at $3.9 million (Q2 2026), $3.9 million (Q1 2026), and $3.5 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.67 Bn | 192.69 Bn | 7.24 Bn | 6.54 Bn |
| 2 | Gilead Sciences | 180.06 Bn | 176.88 Bn | 6.22 Bn | 18.20 Bn |
| 3 | Vertex Pharmaceuticals | 131.44 Bn | 123.59 Bn | 2.84 Bn | 2.09 Bn |
| 4 | Regeneron Pharmaceuticals | 81.94 Bn | 73.95 Bn | 3.93 Bn | 3.00 Bn |
| 5 | Argenx Se | 60.28 Bn | 55.10 Bn | 1.37 Bn | -1.05 Bn |
| 6 | Moderna | 53.87 Bn | 48.73 Bn | 52.00 Mn | 960.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.15 Bn | 29.85 Bn | 992.69 Mn | 1.06 Bn |
| 8 | Biogen | 31.88 Bn | 30.60 Bn | 1.96 Bn | 2.60 Bn |
| 9 | Roivant Sciences | 29.16 Bn | 29.16 Bn | 1.16 Mn | 367.83 Mn |
| 10 | Talphera | 93.28 Mn | 93.28 Mn | - | 3.92 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.92 Mn |
| Mar 31, 2026 | 3.95 Mn |
| Dec 31, 2025 | 3.45 Mn |
| Sep 30, 2025 | 3.42 Mn |
| Jun 30, 2025 | 3.69 Mn |
| Mar 31, 2025 | 2.94 Mn |
| Dec 31, 2024 | 3.00 Mn |
| Sep 30, 2024 | 3.75 Mn |
| Jun 30, 2024 | 4.27 Mn |
| Mar 31, 2024 | 4.24 Mn |
| Dec 31, 2023 | 4.56 Mn |
| Sep 30, 2023 | 3.43 Mn |
| Jun 30, 2023 | 4.22 Mn |
| Dec 31, 2022 | 5.89 Mn |
| Sep 30, 2022 | 4.52 Mn |
| Jun 30, 2022 | 9.96 Mn |
| Mar 31, 2022 | 9.44 Mn |
| Dec 31, 2021 | 8.18 Mn |
| Sep 30, 2021 | 10.50 Mn |
| Jun 30, 2021 | 10.46 Mn |